Lilly’s $2.3B JAK2 Bet Just Showed Its First Cards — and the Myelofibrosis Market Won’t Be the Same

At the European Hematology Association annual meeting on June 13, 2026, a single slide quietly threatened the most dominant franchise in hematologic oncology. The slide showed spleen volume reduction data from a Phase 1 trial called AJX-101. The drug was AJ1-11095. The number that stopped the room: 70% of patients who had already failed a type I JAK inhibitor achieved at least 35% spleen volume reduction as a best response. Eighty-three percent hit the 25% threshold. For a population that medicine has effectively written off, those are not Phase 1 numbers. Those are registration-enabling signals.

The consensus narrative around Lilly’s $2.3 billion acquisition of Ajax Therapeutics was always that it was a smart but early-stage bet on a differentiated mechanism. Type II JAK2 inhibition. Novel binding conformation. Potentially less off-target toxicity than the type I agents that currently dominate the market. The story was good science meeting bold capital allocation. What the EHA data suggest is something more commercially urgent: Lilly may have bought the answer to the question nobody in myelofibrosis has been able to answer since ruxolitinib launched over a decade ago.

What do you give a patient after ruxolitinib fails them?

The Franchise That Owns the Field

To understand what Lilly is threatening, start with the scale of what it is threatening. In 2024, ruxolitinib (Jakafi/Jakavi, Incyte/Novartis) generated approximately $1.5 billion across the seven major markets, capturing an estimated 47.6% of the myelofibrosis treatment segment. That is not a market leader. That is a market. Every other approved agent, including pacritinib and momelotinib, competes at the margins — in thrombocytopenic patients, in anemia-complicated cases — because the core ruxolitinib franchise is effectively uncontested on its home turf.

The structural problem with ruxolitinib’s dominance has always been its ceiling, not its floor. The drug works. For the majority of treatment-naive myelofibrosis patients, it reduces spleen volume, manages symptoms, and extends lives. But resistance develops. Spleen responses wane. And when they do, oncologists face a patient population with progressive disease, deteriorating performance status, and no molecularly rational next step. Pacritinib (Blueprint Medicines) was approved for low-platelet patients but carries a boxed warning. Momelotinib (GSK) carved out an anemia niche. Neither addresses the fundamental problem of post-ruxolitinib disease biology at scale.

That gap is worth pausing on, because the commercial opportunity inside it is enormous and almost entirely unpriced.

The IWG-MRT and ELN consensus criteria published in Blood define six response categories for myelofibrosis — complete remission, partial remission, clinical improvement, stable disease, progressive disease, and treatment failure. In post-type I JAK inhibitor patients, the realistic ceiling for currently available salvage options is “clinical improvement” in a minority of cases. Against that baseline, AJ1-11095’s 70% SVR35 rate at any time as a best response reads less like a Phase 1 signal and more like a category disruption — if it holds through later-stage trials.

The Chorus of Competing Interests

Here is where the surface narrative gets complicated. The EHA data are early. Phase 1 trials are designed to establish safety and preliminary dosing, not to power efficacy endpoints. The patient numbers are small. And the myelofibrosis community has been burned before by Phase 1 excitement that did not survive randomized scrutiny. That is a fair caution. But it is not the whole picture, and the stakeholders circling AJ1-11095 are not all reading the same data with the same anxiety.

Incyte’s position is the most exposed. Jakafi represents the core of Incyte’s commercial identity — roughly 70% of its total product revenue by most estimates. The company has invested in combination strategies and lifecycle management, including work with parsaclisib in myelofibrosis, but no approved next-line option bears its label. If AJ1-11095 establishes itself as the standard-of-care rescue therapy for post-ruxolitinib patients, Incyte does not just lose a revenue line. It loses the downstream patient relationship that feeds bone marrow transplant referrals, clinical trial enrollment, and KOL loyalty. That is a structural disruption, not a market share nibble.

Novartis, which commercializes ruxolitinib as Jakavi outside the United States, faces a more nuanced threat. The Swiss company has its own JAK inhibitor history — it had a ruxolitinib co-development stake that made it a beneficiary of the franchise’s rise. But Novartis also has an active hematology portfolio and the commercial infrastructure to in-license or acquire a second-line myelofibrosis asset if AJ1-11095 advances and Lilly decides it needs a global commercial partner. The question of whether Lilly sells the ex-U.S. rights to AJ1-11095, or builds out its own hematology commercial footprint, will define how aggressively it can capture the opportunity it just telegraphed at EHA.

Lilly itself is the most interesting case. The company spent up to $2.3 billion to acquire Ajax Therapeutics and its type II JAK2 mechanism. That is a steep price for a Phase 1 asset in a disease with a patient population measured in tens of thousands, not hundreds of thousands. The commercial math only works at that valuation if AJ1-11095 can anchor a second-line standard of care, achieve premium pricing, and potentially expand into earlier lines of therapy or adjacent JAK2-driven diseases. Polycythemia vera is the obvious adjacency. Primary myelofibrosis post-allogeneic transplant is another. The EHA data are a proof of concept for the mechanism, not a confirmed path to all of those indications — but they make the optionality real in a way that pre-clinical data never could.

Blueprint Medicines, sitting with pacritinib already approved and its own pipeline ambitions in myeloproliferative neoplasms, has the least obvious stake but arguably the most to gain from AJ1-11095’s success. If Lilly normalizes the idea of second-line JAK inhibitor therapy as a distinct treatment paradigm, it validates Blueprint’s argument that the post-ruxolitinib space deserves dedicated clinical investment and premium reimbursement. A rising tide here lifts the sub-indication boats.

The Gap Between the Data and the Deal

The unanswered question hanging over all of this is durability. Spleen volume reduction responses in myelofibrosis are meaningful but perishable. Ruxolitinib itself demonstrates spleen responses in 40% or more of patients — the problem is that those responses erode over 18 to 24 months in a substantial subset. The IWG-MRT criteria explicitly distinguish “best response at any time” from sustained response, and the AJX-101 trial data presented at EHA report the former. Lilly has not yet shown how long those 70% of SVR35 responders stay in response. That is not a criticism. It is a Phase 1 limitation. But it is the number every oncologist in the EHA room was asking about on June 13.

The type II binding mechanism offers a theoretical reason for optimism on this front. By targeting the inactive conformation of JAK2, AJ1-11095 operates through a fundamentally different binding mode than ruxolitinib and the other type I agents. The preclinical hypothesis is that this approach is less susceptible to the resistance mutations that erode type I inhibitor responses over time. If the Phase 2 data confirm durable responses, that hypothesis becomes a commercial narrative. If they do not, AJ1-11095 remains an interesting but incremental option in a crowded salvage setting.

The ruxolitinib franchise generating $1.5 billion annually was built on one genuinely transformative Phase 3 trial. The AJX-101 data suggest AJ1-11095 could be heading toward a similarly definitive moment. Whether Lilly gets there before Incyte figures out how to defend its franchise, before a larger hematology player acquires the asset outright, or before the Phase 2 data introduce their own complications — that is the race the EHA presentation just started.

References

1. PR Newswire — “Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting”
2. Pharmaceutical Executive — “Eli Lilly Enters $2 Billion Agreement to Acquire Ajax Therapeutics”
3. OncLive — “AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post-Type I JAK Inhibitor Myelofibrosis”
4. GlobeNewswire — “Myelofibrosis (MF) Market Epidemiology and Forecast 2034: Jakafi Leads Myelofibrosis Market but New Therapies Poised to Disrupt by 2034”
5. FierceBiotech — “Lilly’s $2.3B Ajax Deal: First Clinical Data Shows JAK Inhibitor Works Right Out of the Gate”
6. Blood / PubMed — “Revised response criteria for myelofibrosis: IWG-MRT and ELN consensus report”